A complete application consists of:
All documents must be in English or include an official English translation.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.
A research opportunity is available in the Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
This project is aimed at evaluating the use of bacteriophage to treat Staphyloccocus aureus colonization and/or disease in order to better combat multi-antibiotic-resistant bacterial pathogens. A major goal of this project is to establish and utilize animal models to investigate the potential of phage treatment against S. aureus to decolonize the upper respiratory tract and/or to treat S. aureus infections. However, other aspects will delve into aspects of the genetics of bacteriophage that are relevant to their deployment in these contexts. These include genetic mechanisms of bacterial resistance to phage and mechanisms of phage adaptation to infect different or new hosts. Under the guidance of a mentor, the participant will be involved with the following project activities: animal models of infection and phage treatment, isolation of mutant bacterial and bacteriophage strains, genetic engineering of bacterial and bacteriophage strains, isolation of bacteriophage from natural sources, next generation DNA sequence analysis.
*Although the application deadline is August 30th, applications will be reviewed on a rolling-basis.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, MD, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
The Homeland Security Presidential Directive-12 (HSPD-12) mandates a background check be completed for both U.S. Citizens and foreign nationals. Foreign nationals must have resided in the U.S. for at least three (3) of the past five (5) years in order for FDA to be able to complete a background check.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should have received a bachelor's or master's degree in one of the relevant fields, or be currently pursuing one of the degrees and will reach completion by June 2019. Degree must have been received within five years of the appointment start date.